A Phase 3 interventional study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 6 Months to 14 Years. Per ClinicalTrials.gov, last updated 2024-08-23.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.
Among the 19 studies testing tolvaptan in Heart Failure, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 18th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 6 Months to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 60 across the 19 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
17 studies in Heart Failure by Otsuka Holdings Co., Ltd.: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 3, and was the 10th registered.
Otsuka Holdings Co., Ltd.’s Heart Failure studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing tolvaptan in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the efficacy, safety, and dose and regimen of tolvaptan in pediatric CHF patients with volume overload
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with volume overload despite having received any of the following diuretic therapies in whom sufficient effects cannot be expected even if the dose of the diuretics is increased or in whom the investigator or subinvestigator judges that increasing the dose of the diuretics is difficult due to concerns regarding electrolyte abnormalities or other side effects
others
Exclusion Criteria:
Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
Drug: Tolvaptan
Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline
The primary endpoint of this trial was the percentage of subjects whose body weight on the day after the third day of treatment with tolvaptan at the evaluation dose (the third day of administration at the evaluation dose) was decreased by 1.7% or more from the weight measured before breakfast (baseline) on the first day of the treatment period (the initial tolvaptan administration day), under the condition that the mean daily urine volume for the 3 days of treatment with tolvaptan at the evaluation dose was higher than the daily urine volume for the pretreatment observation period. The percentage of subjects as well as the exact 95% confidence interval (CI) based on binomial distribution were calculated.
Time frame: Day after Day 3 at evaluation dose
Change Rate From Baseline in Daily Urine Volume
Daily urine volume was measured for the time interval starting at urination (an instruction to urinate) after breakfast and ending at complete urination immediately before administration on the following day. Baseline was 100% and the change rate was calculated like this. Percent change (%) = (\[daily urine volume on the Day1, Day2 and Day3 of the tolvaptan at the evaluation dose\] - \[daily urine volume on baseline\] ) / \[daily urine volume on baseline\] ×100
Time frame: Baseline, Day1, Day2 and Day3 of administration at evaluation dose
Percent Changes From Baseline in Body Weight (kg)
Percent change from baseline in body weight (kg) on the day after the third day of treatment with tolvaptan at the evaluation dose was evaluated. For body weight measured on the day after the third day of administration at the evaluation dose, their percent changes from baseline (before the start of tolvaptan administration on the first day of the treatment period) mean and standard deviation (SD) were calculated. Baseline was 100% and the change rate was alculated like this. Percent change (%) = (\[body weight on the day after the third day of treatment with tolvaptan at the evaluation dose\] - \[body weight on baseline\] ) / \[body weight on baseline\] ×100
Time frame: Day after Day 3 at evaluation dose
Improvement Rates of Lower Limb Edema
The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated
Time frame: Day after Day 3 at evaluation dose
Improvement Rates of Pulmonary Congestion
The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated
Time frame: Day after Day 3 at evaluation dose
| Milestone | Tolvaptan |
|---|---|
| Started | 60 |
| Completed | 46 |
| Not completed | 14 |
| Withdrew: Adverse event | 2 |
| Withdrew: Physician decision | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Serum or blood sodium increased | 4 |
| Withdrew: Serum or blood potassium increased | 4 |
The primary endpoint of this trial was the percentage of subjects whose body weight on the day after the third day of treatment with tolvaptan at the evaluation dose (the third day of administration at the evaluation dose) was decreased by 1.7% or more from the weight measured before breakfast (baseline) on the first day of the treatment period (the initial tolvaptan administration day), under the condition that the mean daily urine volume for the 3 days of treatment with tolvaptan at the evaluation dose was higher than the daily urine volume for the pretreatment observation period. The percentage of subjects as well as the exact 95% confidence interval (CI) based on binomial distribution were calculated.
| percentage of participants | Tolvaptan |
|---|---|
| Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline | 22.8 (12.7 to 35.8) |
Daily urine volume was measured for the time interval starting at urination (an instruction to urinate) after breakfast and ending at complete urination immediately before administration on the following day. Baseline was 100% and the change rate was calculated like this. Percent change (%) = (\[daily urine volume on the Day1, Day2 and Day3 of the tolvaptan at the evaluation dose\] - \[daily urine volume on baseline\] ) / \[daily urine volume on baseline\] ×100
| percentage of urine volume (mL) | Tolvaptan |
|---|---|
| Day 1 | 53.1 ± 52.9 |
| Day 2 | 47.8 ± 43.3 |
| Day 3 | 45.8 ± 29.3 |
Percent change from baseline in body weight (kg) on the day after the third day of treatment with tolvaptan at the evaluation dose was evaluated. For body weight measured on the day after the third day of administration at the evaluation dose, their percent changes from baseline (before the start of tolvaptan administration on the first day of the treatment period) mean and standard deviation (SD) were calculated. Baseline was 100% and the change rate was alculated like this. Percent change (%) = (\[body weight on the day after the third day of treatment with tolvaptan at the evaluation dose\] - \[body weight on baseline\] ) / \[body weight on baseline\] ×100
| percentage of body weight (kg) | Tolvaptan |
|---|---|
| Percent Changes From Baseline in Body Weight (kg) | -0.371 ± 2.470 |
The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated
| percentage of participants | Tolvaptan |
|---|---|
| Improvement Rates of Lower Limb Edema | 68.6 (50.7 to 83.1) |
The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below: * Markedly improved * Improved * Unchanged * Deteriorated
| percentage of participants | Tolvaptan |
|---|---|
| Improvement Rates of Pulmonary Congestion | 51.6 (33.1 to 69.8) |
Collected over Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 16 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan | 0/60 (0%) | 1/60 (1.7%) | 25/60 (41.7%) |
| Event | Tolvaptan |
|---|---|
| Cardiac failure chronicCardiac disorders | 1/60 |
| Event | Tolvaptan |
|---|---|
| ThirstGeneral disorders | 4/60 |
| AnaemiaBlood and lymphatic system disorders | 2/60 |
| ConstipationGastrointestinal disorders | 2/60 |
| Dry mouthGastrointestinal disorders | 2/60 |
| VomitngGastrointestinal disorders | 2/60 |
| PyrexiaGeneral disorders | 2/60 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/60 |
| NeutropeniaBlood and lymphatic system disorders | 1/60 |
| Cardiovascular insufficiencyCardiac disorders | 1/60 |
| Erythema of eyelidEye disorders | 1/60 |
The FAS included 59 of 60 subjects (98.3%) who received the IMP. One subject was excluded from the FAS because the subject received the IMP at least once, and discontinued the trial before the daily urine volume data on Day 1 were obtained.
| Age, Continuous(years) | Tolvaptan |
|---|---|
| Mean | 5.44 ± 5.03 |
| Age, Customized(Participants) | Tolvaptan |
|---|---|
| Age group — 6 months to less than 2 years | 20 |
| Age group — 2 years to less than 7 years | 16 |
| Age group — 7 years to less than 15 years | 23 |
| Sex: Female, Male(Participants) | Tolvaptan |
|---|---|
| Female | 28 |
| Male | 31 |
| Race/Ethnicity, Customized(Participants) | Tolvaptan |
|---|---|
| Asian | 59 |
| Region of Enrollment(participants) | Tolvaptan |
|---|---|
| Japan | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Mar 2018 to primary completion in Jul 2021, 40 months.
Results were first posted in Aug 2024, 3 years 1 month after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 40 months is above that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →